BR112022020042A2 - Método para tratar hiperinflamação com o uso de células-tronco ou precursoras de linhagem mesenquimal - Google Patents

Método para tratar hiperinflamação com o uso de células-tronco ou precursoras de linhagem mesenquimal

Info

Publication number
BR112022020042A2
BR112022020042A2 BR112022020042A BR112022020042A BR112022020042A2 BR 112022020042 A2 BR112022020042 A2 BR 112022020042A2 BR 112022020042 A BR112022020042 A BR 112022020042A BR 112022020042 A BR112022020042 A BR 112022020042A BR 112022020042 A2 BR112022020042 A2 BR 112022020042A2
Authority
BR
Brazil
Prior art keywords
hyperinflamation
stem cells
treat
mesenchymal
line precursor
Prior art date
Application number
BR112022020042A
Other languages
English (en)
Portuguese (pt)
Inventor
Itescu Silviu
Original Assignee
Mesoblast Int Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901052A external-priority patent/AU2020901052A0/en
Application filed by Mesoblast Int Sarl filed Critical Mesoblast Int Sarl
Publication of BR112022020042A2 publication Critical patent/BR112022020042A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112022020042A 2020-04-03 2021-04-01 Método para tratar hiperinflamação com o uso de células-tronco ou precursoras de linhagem mesenquimal BR112022020042A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
AU2020901052A AU2020901052A0 (en) 2020-04-03 Method for treating hyperinflammation which comprise administering mesenchymal lineage precursor or stem cells
AU2020901124A AU2020901124A0 (en) 2020-04-08 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020902312A AU2020902312A0 (en) 2020-07-06 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020902425A AU2020902425A0 (en) 2020-07-14 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020903041A AU2020903041A0 (en) 2020-08-25 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020903694A AU2020903694A0 (en) 2020-10-12 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020904312A AU2020904312A0 (en) 2020-11-23 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
PCT/EP2021/058683 WO2021198454A1 (en) 2020-04-03 2021-04-01 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells

Publications (1)

Publication Number Publication Date
BR112022020042A2 true BR112022020042A2 (pt) 2022-11-22

Family

ID=77927537

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020042A BR112022020042A2 (pt) 2020-04-03 2021-04-01 Método para tratar hiperinflamação com o uso de células-tronco ou precursoras de linhagem mesenquimal

Country Status (9)

Country Link
US (1) US20230165904A1 (https=)
EP (1) EP4125957A1 (https=)
JP (1) JP2023520233A (https=)
KR (1) KR20220164741A (https=)
CN (1) CN115361959A (https=)
AU (1) AU2021245369A1 (https=)
BR (1) BR112022020042A2 (https=)
CA (1) CA3173216A1 (https=)
WO (1) WO2021198454A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
EP4181935A1 (en) * 2020-07-20 2023-05-24 Brainstorm Cell Therapeutics Ltd. Methods and compositions for treating lung conditions
CN112826833A (zh) * 2020-07-30 2021-05-25 中国人民解放军总医院第五医学中心 间充质干细胞在制备新冠肺炎引起的肺损伤修复药物中的应用
US12067745B2 (en) 2022-09-27 2024-08-20 Kla Corporation Image pre-processing for overlay metrology using decomposition techniques

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
CN101511872A (zh) * 2006-08-29 2009-08-19 为人技术株式会社 用于抑制凋亡的药物组合物及其递送方法
US20120087868A1 (en) * 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
US20140134140A1 (en) * 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections
WO2015016761A2 (en) * 2013-08-01 2015-02-05 Isletone Ab Mscs in the treatment of inflammatory pulmonary diseases
JP6173157B2 (ja) * 2013-10-02 2017-08-02 日本製薬株式会社 Ｉｌ−１７産生抑制組成物
CN110101873A (zh) * 2018-10-27 2019-08-09 广州呼吸健康研究院 一种利用il-10转基因的干细胞治疗ards的方法
CN110108883A (zh) * 2018-10-27 2019-08-09 广州呼吸健康研究院 用于筛选与靶治疗ards患者的msc精准医学的标志物组合

Also Published As

Publication number Publication date
CA3173216A1 (en) 2021-10-07
KR20220164741A (ko) 2022-12-13
JP2023520233A (ja) 2023-05-16
CN115361959A (zh) 2022-11-18
AU2021245369A1 (en) 2022-11-03
US20230165904A1 (en) 2023-06-01
WO2021198454A1 (en) 2021-10-07
EP4125957A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
BR112022020042A2 (pt) Método para tratar hiperinflamação com o uso de células-tronco ou precursoras de linhagem mesenquimal
MX2024003145A (es) Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
BR112022018022A2 (pt) Método para tratar doença inflamatória intestinal ii
AR081450A1 (es) Tratamiento de sarcoidosis usando celulas madre de placenta
CO6331301A2 (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
BR112022016448A2 (pt) Método para tratamento de doença do enxerto contra hospedeiro crônica
BR112022017557A2 (pt) Método para tratar doenças pulmonares inflamatórias com o uso de células-tronco ou precursoras de linhagem mesenquimal
BR112023020669A2 (pt) Terapias de combinação para o tratamento de câncer
BR112022001054A2 (pt) Inibidores enzimáticos
BR112022001341A2 (pt) Inibidores de enzima
CR20210514A (es) USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)
BR112022017560A2 (pt) Método para tratar doença inflamatória intestinal i
CR20200061A (es) Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de células b grandes difusas (dlbcl)
BR112023021840A2 (pt) Método para tratar síndrome da dificuldade respiratória aguda (ards) com o uso de percursor de linhagem mesenquimal ou células-tronco
BR112016000658A2 (pt) pancreatina de alta atividade, processo para a preparação de pancreatina de aa tendo atividade lipásica específica de pelo menos aproximadamente 120 usp iu/mg e método de tratamento de um paciente sujeito a uma condição patológica associada com a insuficiência enzimática pandreática
BR112023018654A2 (pt) Compostos antibacterianos
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
BR112014016950A2 (pt) métodos de promoção da cicatrização de úlceras diabéticas utilizando beta-hidróxi-beta-metilbutirato com arginina e glutamina
MX2022005973A (es) Inhibidores de akt para mejorar la persistencia de celulas t quimericas.
BR112023018655A2 (pt) Compostos antibacterianos
CL2023003777A1 (es) Métodos de tratamiento con moduladores del receptor de esfingosina-1-fosfato (s1p)
BR112022020392A2 (pt) Método para tratar um indivíduo que tem doença de huntington, inibidor do bromodomínio 9, e, uso de um inibidor do bromodomínio 9
BR112022021006A2 (pt) Métodos para reduzir ou prevenir a colonização de clostridioides difficile
BR112019008241A2 (pt) tratamento do prurigo nodular